Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy.
Acta Paediatr. 2010 Apr;99(4):544-9. doi: 10.1111/j.1651-2227.2009.01668.x. Epub 2010 Jan 27.
To evaluate the prescription rate of respiratory drugs (ATC code R03) in an Italian community setting and to estimate the extent of off-label use by both age and indication.
A cohort study aimed at evaluating prescriptions of drugs with ATC code R03 was conducted for the period 2002-2006. Data source was the PEDIANET Database.
Ninety percent of R03 prescriptions are covered by 11 active substances or combinations, corresponding to 67 medicinal products. Inhaled corticosteroids are the most prescribed anti-asthmatic agents, followed by short-acting beta2 mimetics. The mean off-label rate is 19 and 56%, by age and indication respectively. The majority of off-label uses is among children under the age of 2. Five active substances are used at dosages not supported by adequate dose-finding studies.
In Italy, many respiratory drugs are approved for the treatment of paediatric respiratory diseases, but a remarkable percentage of their prescriptions is off-label. This pharmaco-utilization study demonstrates that there is a need to perform clinical studies aimed at increasing the current knowledge on marketed paediatric drugs, and to revise and re-label the existing regulatory documents to reduce their off-label uses.
评估意大利社区环境中呼吸系统药物(ATC 代码 R03)的处方率,并按年龄和适应证估计其标签外使用的程度。
开展了一项旨在评估 2002-2006 年期间 R03 类药物处方的队列研究。数据来源是 PEDIANET 数据库。
90%的 R03 处方涵盖了 11 种活性物质或组合,对应 67 种药物。吸入性皮质类固醇是最常开的抗哮喘药物,其次是短效β2 激动剂。按年龄和适应证划分,平均标签外使用率分别为 19%和 56%。标签外使用主要发生在 2 岁以下儿童中。有 5 种活性物质的剂量未经过充分的剂量发现研究支持。
在意大利,许多呼吸系统药物被批准用于治疗儿科呼吸系统疾病,但相当一部分处方是标签外使用的。这项药物利用研究表明,有必要开展临床研究,以增加对已上市儿科药物的现有知识,并修订和重新标记现有的监管文件,以减少其标签外使用。